广谱炎症蛋白筛查发现血清CCL19是IgG4相关疾病活动性的新型生物标志物
在80例IgG4-RD患者(含28例纵向配对样本)和80名匹配健康供者中,定量ELISA验证了CCL19的全身性升高,且CCL19与IgG4互补区分活动期与缓解期。
要点
- CCL19是IgG4-RD活动性的新型候选生物标志物。
- CCL19随治疗缓解下降、复发时升高,与IgG4动态相似。
- CCL19与IgG4互补,有助于识别复发性疾病。
核心结论
- CCL19是IgG4-RD纵向监测疾病活动性的新型且有前景的生物标志物,并可能为识别复发性疾病提供补充价值。
研究设计与样本
- 采用无监督层次聚类、受试者工作特征曲线和统计分析研究区分IgG4-RD的生物标志物。
- 用定量ELISA在80例IgG4-RD患者(含28例纵向配对样本)和80名年龄、性别、种族匹配的健康供者中验证发现。
主要发现
- 仅CCL19在治疗诱导缓解后较活动性IgG4-RD下降。
- CCL19与疾病活动性和严重度的临床及实验室参数相关。
- 定量ELISA验证了IgG4-RD患者CCL19的全身性升高。
- CCL19在治疗应答中动态下降、随后复发时升高,表现与IgG4相似;CCL19与IgG4互补区分活动性疾病与缓解。
关键数值与推荐
- 在80例IgG4-RD患者(含28例纵向配对样本)和80名匹配健康供者中经定量ELISA验证CCL19升高。
临床怎么用
- CCL19可用于IgG4-RD疾病活动性的纵向监测,并与IgG4互补识别复发性疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: IgG4-related disease (IgG4-RD) is a chronic immune-mediated disease characterised by mass-forming lesions. The smouldering tempo and often asymptomatic nature of IgG4-RD pose challenges in the monitoring of disease activity. The goal of this study is to identify novel biomarkers capable of distinguishing active disease from remission. METHODS: Ninety-two inflammation-associated proteins were measured across 67 patients with IgG4-RD, 49 healthy donors (HDs), and 21 patients with sarcoidosis. Statistical analyses were adjusted for age, sex, race, and false discovery rate. Biomarkers that distinguished IgG4-RD were studied by unsupervised hierarchical clustering, receiver operator characteristic curves, and statistical analyses. Quantitative enzyme-linked immunosorbent assay (ELISA) was used to validate findings in a cohort of 80 patients with IgG4-RD, including 28 patients with paired longitudinal samples, and 80 age, sex, and race-matched HDs. RESULTS: Twelve inflammation-associated proteins distinguished IgG4-RD. Although most markers correlated with one another, CCL19, CCL2, and CCL13 were the most distinguishing of IgG4-RD. Among these, only CCL19 decreased during treatment-induced remission relative to active IgG4-RD. CCL19 correlated with clinical and laboratory parameters of disease activity and severity. Quantitative ELISA validated the systemic elevation of CCL19 in patients with IgG4-RD. CCL19 performed similarly to IgG4 in dynamically declining in response to treatment and increasing with subsequent relapse. Importantly, CCL19 and IgG4 supplemented one another in distinguishing active disease from remission. CONCLUSIONS: CCL19 is a novel and promising biomarker for the longitudinal monitoring of disease activity in patients with IgG4-RD and may provide supplemental value to IgG4 in identifying relapsing disease.
引用
- Bonaso F, Jiang B, Yockey LJ, et al. Broad screening of inflammation-associated proteins identifies serum CCL19 as a novel biomarker of disease activity in IgG4-related disease. Ann Rheum Dis. 2026. PMID: 42128703. doi:10.1016/j.ard.2026.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。